Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-17T01:43:30.655Z Has data issue: false hasContentIssue false

13 - Zinc and tetrathiomolybdate for the treatment of Wilson disease

from SECTION IV - METAL ION THERAPY

Published online by Cambridge University Press:  17 November 2010

By
George J. Brewer
Edited by
Jess G. Thoene
Jess G. Thoene
Affiliation:
University of Michigan, Ann Arbor
Get access
Type
Chapter
Information
Small Molecule Therapy for Genetic Disease , pp. 185 - 201
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brewer, GJ. Recognition, diagnosis, and management of Wilson's disease. Exp Biol Med. 2000;223:39–46CrossRefGoogle ScholarPubMed
Schilsky, ML. Wilson disease: Genetic basis of copper toxicity and natural history. Semin Liver Dis. 1996;16:83–95CrossRefGoogle ScholarPubMed
Scheinberg, IH, Sternlieb, I. Wilson's disease. Smith, L.H.J., ed. Major Problems in Internal Medicine, W.B. Saunders Company, Philadelphia, 1–171, 1984Google Scholar
Brewer, GJ. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management, Kluwer Academic Publishers, Boston, 2001CrossRefGoogle Scholar
Brewer, GJ. Wilson's disease. Fauci, AS, Braunward, E, Kasper, DL, Hauser, Sl, Longo, DL, Jameson, JL, Loscalzo, J, eds. Harrison's Principles of Internal Medicine, 17th edition, McGraw-Hill Companies, Inc., New York, 2449–2452, 2008Google Scholar
Brewer, GJ, Yuzbasiyan-Gurkan, V. Wilson disease. Medicine. 1992;71:139–164CrossRefGoogle ScholarPubMed
Bhave, SA, Pandit, AN, Pradhan, AM, Sidhaye, DG, Kantarjian, A, Williams, A, Talbot, IC, Tanner, MS. Liver disease in India. Arch Dis Child. 1982;57:922–928CrossRefGoogle ScholarPubMed
Starosta-Rubinstein, S, Young, AB, Kluin, K, Hill, G, Aisen, AM, Gabrielsen, T, Brewer, GJ. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol. 1987;44:365–370CrossRefGoogle ScholarPubMed
Fink, JK, Hedera, P, Brewer, GJ. Hepatolenticular degeneration (Wilson's disease). The Neurologist. 1999;5:171–185CrossRefGoogle Scholar
Brewer, GJ, Fink, JK, Hedera, P. Diagnosis and treatment of Wilson's disease. Semin Neurol. 1999;19:261–270CrossRefGoogle ScholarPubMed
Brewer, GJ. Behavioral abnormalities in Wilson's disease. Weiner, WJ, Lang, AE, Anderson, KE, eds. Behavioral Neurology of Movement Disorders, 2nd edition, Lippincott, Williams & Wilkins, Philadelphia, 262–274, 2005Google Scholar
Sternlieb, I, Scheinberg, IH. Prevention of Wilson's disease in asymptomatic patients. N Engl J Med. 1968;278:352–359CrossRefGoogle ScholarPubMed
Brewer, GJ, Dick, RD, Yuzbasiyan-Gurkan, V, Johnson, V, Wang, Y. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med. 1994;123:849–858Google ScholarPubMed
Nazer, H, Ede, RJ, Mowat, AP, Williams, R. Wilson's disease: Clinical presentation and use of prognostic index. Gut. 1986;27:1377–1381CrossRefGoogle ScholarPubMed
Bull, PC, Thomas, GR, Rommens, JM, Forbes, JR, Cox, DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327–337CrossRefGoogle ScholarPubMed
Tanzi, RE, Petrukhin, K, Chernov, I, Pellequer, JL, Wasco, W, Ross, B, Romano, DM, Parano, E, Pavone, L, Brzustowicz, LM Devoto M, Peppercorn, J, Bush, AI, Sternlieb, I, Pirastu, M, Gusella, JF, Evgrafov, O, Penchaszadeh, GK, Honig, B, Edelman, IS, Soare, MB, Scheinberg, IH, Gilliam, TC. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344–350CrossRefGoogle ScholarPubMed
Yamaguchi, Y, Heiny, ME, Gitlin, JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun. 1993;197:271–277CrossRefGoogle ScholarPubMed
Frommer, DJ. Defective biliary excretion of copper in Wilson's disease. Gut. 1974;15:125–129CrossRefGoogle ScholarPubMed
Cox, DW, Roberts, E. Wilson Disease, 2006 vol. Gene Clinics, University of Washington, Seattle, 1999Google Scholar
Walshe, JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487–495CrossRefGoogle ScholarPubMed
Brewer, GJ, Terry, CA, Aisen, AM, Hill, GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol. 1987;44:490–493CrossRefGoogle ScholarPubMed
Walshe, JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1:643–647CrossRefGoogle ScholarPubMed
Walshe, JM. The management of pregnancy in Wilson's disease treated with trientine. Q J Med. 1986;58:81–87Google ScholarPubMed
Askari, FK, Greenson, J, Dick, RD, Johnson, VD, Brewer, GJ. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med. 2003;142:385–390CrossRefGoogle ScholarPubMed
Brewer, GJ, Askari, F, Lorincz, MT, Carlson, M, Schilsky, M, Kluin, KJ, Hedera, P, Moretti, P, Fink, JK, Tankanow, R, Dick, RB, Sitterly, J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521–527CrossRefGoogle Scholar
Schouwink, G. De hepatocecerebrale degeneratie, met een onderzoek naar de zonkstrofwisseling. MD thesis (with a summary in English, French, and German). University of Amsterdam, 1961Google Scholar
Hoogenraad, TU, Hamer, CJ, Hattum, J. Effective treatment of Wilson's disease with oral zinc sulphate: Two case reports. Br Med J (Clin Res Ed). 1984;289:273–276CrossRefGoogle ScholarPubMed
Hoogenraad, TU, Hattum, J, Hamer, CJA. Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients. J Neurol Sci. 1987;77:137–146CrossRefGoogle Scholar
Brewer, GJ, Hill, GM, Prasad, AS, Cossack, ZT, Rabbani, P. Oral zinc therapy for Wilson's disease. Ann Intern Med. 1983;99:314–319CrossRefGoogle ScholarPubMed
Hill, GM, Brewer, GJ, Prasad, AS, Hydrick, CR, Hartmann, . Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology. 1987;7:522–528CrossRefGoogle ScholarPubMed
Hill, GM, Brewer, GJ, Juni, JE, Prasad, AS, Dick, RD. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci. 1986;292:344–349CrossRefGoogle ScholarPubMed
Brewer, GJ, Hill, GM, Dick, RD, Nostrant, TT, Sams, JS, Wells, JJ, Prasad, AS. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med. 1987;109:526–531Google ScholarPubMed
Brewer, GJ, Hill, G, Prasad, A, Dick, R. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med. 1987;184:446–455CrossRefGoogle ScholarPubMed
Yuzbasiyan-Gurkan, V, Brewer, GJ, Abrams, GD, Main, B, Giacherio, D. Treatment of Wilson's disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease. J Lab Clin Med. 1989;114:520–526Google ScholarPubMed
Brewer, GJ, Yuzbasiyan-Gurkan, V, Lee, DY, Appelman, H. Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med. 1989;114:633–638Google ScholarPubMed
Lee, DY, Brewer, GJ, Wang, YX. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med. 1989;114:639–645Google Scholar
Brewer, GJ, Yuzbasiyan-Gurkan, V, Dick, R. Zinc therapy of Wilson's disease: VIII. Dose response studies. J Trace Elem Exp Med. 1990;3:227–234Google Scholar
Brewer, GJ, Yuzbasiyan-Gurkan, V, Johnson, V. Treatment of Wilson's disease with zinc. IX: Response of serum lipids. J Lab Clin Med. 1991;118:466–470Google ScholarPubMed
Yuzbasiyan-Gurkan, V, Grider, A, Nostrant, T, Cousins, RJ, Brewer, GJ. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med. 1992;120:380–386Google ScholarPubMed
Brewer, GJ, Yuzbasiyan-Gurkan, V, Johnson, V, Dick, RD, Wang, Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12:26–30CrossRefGoogle ScholarPubMed
Brewer, GJ, Yuzbasiyan-Gurkan, V, Johnson, V, Dick, RD, Wang, Y. Treatment of Wilson's disease with zinc XII: Dose regimen requirements. Am J Med Sci. 1993;305:199–202CrossRefGoogle ScholarPubMed
Brewer, GJ, Johnson, V, Kaplan, J. Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J Lab Clin Med. 1997;129:649–652CrossRefGoogle ScholarPubMed
Brewer, GJ, Dick, RD, Johnson, VD, Brunberg, JA, Kluin, KJ, Fink, JK. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J Lab Clin Med. 1998;132:264–278CrossRefGoogle ScholarPubMed
Brewer, GJ, Dick, RD, Johnson, VD, Fink, JK, Kluin, KJ, Daniels, S. Treatment of Wilson's disease with zinc XVI: Treatment during the pediatric years. J Lab Clin Med. 2001;137:191–198CrossRefGoogle ScholarPubMed
Brewer, GJ, Johnson, VD, Dick, RD, Fink, JK, Kluin, KJ, Hedera, P. Treatment of Wilson's disease with zinc XVII: Treatment during pregnancy. Hepatology. 2000;31:364–370CrossRefGoogle ScholarPubMed
Marcellini, M, Di Ciommo, V, Callea, F, Devito, R, Comparcola, D, Sartorelli, MR, Carelli, G, Nobili, B. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: A single-hospital, 10-year follow-up study. J Lab Clin Med. 2005;145:139–143CrossRefGoogle ScholarPubMed
Brewer, GJ, Dick, RD, Yuzbasiyan-Gurkan, V, Tankanow, R, Young, AB, Kluin, KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol. 1991;48:42–47CrossRefGoogle ScholarPubMed
Brewer, GJ, Dick, RD, Johnson, V, Wang, Y, Yuzbasiyan-Gurkan, V, Kluin, K, Fink, JK, Aisen, A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994;51:545–554CrossRefGoogle ScholarPubMed
Brewer, GJ, Johnson, V, Dick, RD, Kluin, KJ, Fink, JK, Brunberg, JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996;53:1017–1025CrossRefGoogle ScholarPubMed
Brewer, GJ, Hedera, P, Kluin, KJ, Carlson, M, Askari, F, Dick, RB, Sitterly, J, Fink, JK. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379–385CrossRefGoogle Scholar
Bremner, I, Mills, CF, Young, BW. Copper metabolism in rats given di- or trithiomolybdates. J Inorg Biochem. 1982;16:109–119CrossRefGoogle ScholarPubMed
Gooneratne, SR, Howell, JM, Gawthorne, JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr. 1981;46:469–480CrossRefGoogle ScholarPubMed
Mills, CF, El-Gallad, TT, Bremner, I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem. 1981;14:189–207CrossRefGoogle ScholarPubMed
Mills, CF, El-Gallad, TT, Bremner, I, Weham, G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem. 1981;14:163–175CrossRefGoogle ScholarPubMed
Gartner, EM, Griffith, KA, Pan, Q, Brewer, GJ, Henja, GF, Merajver, SD, Zalupski, MM. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs. 2009;27(2):159–165; epub 2008 Aug 20CrossRefGoogle ScholarPubMed
Henry, NL, Dunn, R, Merjaver, S, Pan, Q, Pienta, KJ, Brewer, G, Smith, DC. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology. 2006;71:168–175CrossRefGoogle ScholarPubMed
Redman, BG, Esper, P, Pan, Q, Dunn, RL, Hussain, HK, Chenevert, T, Brewer, GJ, Merajver, SD. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res. 2003;9:1666–1672Google ScholarPubMed
Pass, HI, Brewer, GJ, Dick, R, Carbone, M, Merajver, S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: Final results. Ann Thorac Surg. 2008;86:383–389CrossRefGoogle ScholarPubMed
Brewer, GJ, Yuzbasiyan-Gurkan, V, Dick, R, Wang, Y, Johnson, V. Does a vegetarian diet control Wilson's disease?J Am Coll Nutr. 1993;12:527–530CrossRefGoogle ScholarPubMed
Mishra, D, Kalra, V, Seth, R. Failure of prophylactic zinc in Wilson disease. Indian Pediatr. 2008;45:151–153Google ScholarPubMed
Walshe, JM, Munro, NA. Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol. 1995;52:10–11CrossRefGoogle Scholar
Lang, CJ, Rabas-Kolominsky, P, Engelhardt, A, Kobras, G, Konig, HJ. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol. 1993;50:1007–1008CrossRefGoogle ScholarPubMed
Brewer, GJ, Askari, F, Lorincz, MT, Carlson, M. Kluin, KJ, Fink, JK, Dick, RB, Sitterly, J. Treatment of Wilson's disease with ammonium tetrathiomolybdate V: New dosage regimen to reduce side effects. In preparation

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×